Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint

COMPASS Pathways plc

Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.
No serious adverse events; common AEs mild: headache (50%), nausea (36.4%), crying (27.3%), fatigue (27.3%).
Mean CAPS-5 total score reduced 29.9 points at week 4 and 29.5 points at week 12 from baseline of 47.5.
Response rate (≥15-point CAPS-5 improvement) 81.8% at week 4 and 77.3% at week 12; remission rate 63.6% at week 4.
No patient withdrawals and no return to antidepressant medication during the 12-week study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.